|ITCI -- USA Stock|| |
USD 18.46 0.19 1.02%
Vice President and CFO
Mr. Lawrence J. Hineline, CPA, is Chief Financial Officer, Vice President Finance, Treasurer, Assistant Secretary of IntraCellular Therapies, Inc. Mr. Hineline also served as the Secretary of the Company from August 2013 until September 2014. From December 2000 to November 2003, Mr. Hineline was the Vice President of Finance and Chief Financial Officer of Functional Genetics, Inc. Prior to that, Mr. Hineline served as the Vice President of Finance of North American Vaccine, Inc. and its predecessor companies from 1993 to 2000, and he served as Corporationrationrate Controller from 1989 to 1993. During this time, Mr. Hineline oversaw the growth of the accounting function and its systems for the company that emerged as a startup and was later acquired by Baxter Health Care
Age: 59 President Since 2014 CPA
Hineline is a licensed CPA in the State of Maryland and received his Bachelor?s Degree from the University of Maryland Baltimore County.
Lawrence Hineline Latest Insider Activity
The company has return on total asset (ROA)
of (17.14) %
which means that it has lost $17.14 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE)
of (27.39) %
meaning that it created substantial loss on money invested by shareholders.
Intra-Cellular Therapies, Inc., a biopharmaceutical company, engages in developing novel drugs for the treatment of neuropsychiatric and neurodegenerative diseases. Intra-Cellular Therapies, Inc. is headquartered in New York, New York. Intra Cellular operates under Biotechnology classification in USA and traded on NASDAQ. It employs 49 people.Intra Cellular Therapies (ITCI) is traded on NASDAQ in USA. It is located in NEW YORK, U.S.A and employs 49 people. Intra Cellular is listed under Pharmaceutical Products category by Fama And French industry classification.
Intra Cellular Thera Leadership Team
|Lawrence Wennogle, President, Ph.D|
|Christopher Alafi, Director|
|Michael Rawlins, Director|
|Robert Nostrand, Director|
|Richard Lerner, Director|
|Robert Davis, President, Ph.D|
|Allen Fienberg, Founder, Ph.D|
|Michael Halstead, SVP|
|Sharon Mates, Chairman, Ph.D|
|Andrew Satlin, President|
|Juan Sanchez, President|
|Rory Riggs, Director, MBA|
|Joel Marcus, Director|
|Kimberly Vanover, VP, Ph.D|
|Lawrence Hineline, President, CPA|
Stock Performance Indicators
Most of Macroaxis users are currently bullish on Intra Cellular Therapies. What is your judgment towards investing in Intra Cellular Therapies? Are you bullish or bearish?
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations